Evidence map›Paper›PMID 33148678›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2021

Clearing the Haze: What Do We Still Need to Learn about Electronic Nicotine Delivery Systems?

Lisa M Fucito, Hannah Malinosky, Stephen R Baldassarri, Roy S Herbst

Abstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lisa M FucitoDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. lisa.fucito@yale.edu.
Hannah MalinoskyDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Stephen R BaldassarriDepartment of Internal Medicine, Section of Pulmonary, Critical Care & Sleep Medicine, Yale University School of Medicine, New Haven, Connecticut.
Roy S HerbstYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Yale Center for the Study of Tobacco Product Use and Addiction (YCSTP) Project 2: Addictive Threshold of Nicotine and the Impact of SweetenersU54DA036151 · NIDA · YALE UNIVERSITY · PI LISA M FUCITO · 2018 to 2026
$41.6M
Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · 2015 to 2026
$31.1M
Understanding Factors that Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine ReceptorsK23DA045957 · NIDA · YALE UNIVERSITY · PI BALDASSARRI, STEPHEN · 2018 to 2022
$983k
NCATS NIH HHS UL1 TR001863NCI NIH HHS P50 CA196530NIDA NIH HHS K23 DA045957NIDA NIH HHS U54 DA036151
6 · The paper itself

Abstract

Electronic nicotine delivery systems (ENDS; i.e., electronic cigarettes, e-cigarettes, vaping devices, vape pens) were introduced to the U.S. market in 2007 as a potential harm reduction alternative for people who smoked combustible cigarettes. Since that time, ENDS popularity grew very quickly, particularly among individuals who smoke cigarettes. However, young people and never smokers also started using ENDS, cohorts for whom these products were not intended. There are now a broad range of devices and e-liquid constituents. ENDS devices vary considerably in their design and generation of potentially toxic chemicals, with higher power devices likely much more hazardous than lower power devices. This landscape may further change after September 9, 2020, when all ENDS manufacturers are required to submit a premarket tobacco product application to the FDA to obtain authorization for marketing. Research has not kept pace with this rapidly changing technology and important questions remain regarding the relative benefits versus risks of ENDS. In light of these challenges, we propose key ENDS research priorities to address these gaps.

Indexed as

Electronic Nicotine Delivery SystemsCardiovascular DiseasesCigarette SmokingHumansNeoplasmsNicotineRespiratory Tract DiseasesSmoking CessationVapingNicotine

Identifiers

PMID33148678
PMCPMC8324047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.